Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2016 Nov;14(11):1593-1601.e2.
doi: 10.1016/j.cgh.2016.02.016. Epub 2016 Feb 22.

Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease

Aurelien Amiot  1 , Jean-Charles Grimaud  2 , Laurent Peyrin-Biroulet  3 , Jerome Filippi  4 , Benjamin Pariente  5 , Xavier Roblin  6 , Anthony Buisson  7 , Carmen Stefanescu  8 , Caroline Trang-Poisson  9 , Romain Altwegg  10 , Philippe Marteau  11 , Thibaud Vaysse  12 , Anne Bourrier  13 , Stephane Nancey  14 , David Laharie  15 , Matthieu Allez  16 , Guillaume Savoye  17 , Jacques Moreau  18 , Charlotte Gagniere  19 , Lucine Vuitton  20 , Stephanie Viennot  21 , Alexandre Aubourg  22 , Anne-Laure Pelletier  23 , Guillaume Bouguen  24 , Vered Abitbol  25 , Yoram Bouhnik  8 ; Observatory on Efficacy and of Vedolizumab in Patients With Inflammatory Bowel Disease Study Group; Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif
Collaborators, Affiliations
Multicenter Study

Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease

Aurelien Amiot et al. Clin Gastroenterol Hepatol. 2016 Nov.

Abstract

Background & aims: Phase 3 trials have shown the efficacy of vedolizumab, which binds to integrin α4β7, in patients with Crohn's disease (CD) or ulcerative colitis (UC). We investigated the effectiveness and safety of vedolizumab in patients who failed anti-tumor necrosis factor therapy.

Methods: From June through December 2014, there were 173 patients with CD and 121 patients with UC who were included in a multicenter nominative compassionate early access program granted by French regulatory agencies. This program provided patients with access to vedolizumab before it was authorized for marketing. Vedolizumab (300 mg) was administered intravenously at weeks 0, 2, and 6, and then every 8 weeks. Disease activity was assessed using the Harvey-Bradshaw Index for CD and the partial Mayo Clinic score for UC. We report results obtained after the 14-week induction phase.

Results: Among the 294 patients treated with vedolizumab (mean age, 39.5 ± 14.0 y; mean disease duration, 10.8 ± 7.6 y; concomitant steroids, 44% of cases), 276 completed the induction period, however, 18 discontinued vedolizumab because of a lack of response (n = 14), infusion-related reaction (n = 2), or infections (n = 2). At week 14, 31% of patients with CD were in steroid-free clinical remission and 51% had a response; among patients with UC, 36% were in steroid-free clinical remission and 50% had a response. No deaths were reported. Severe adverse events occurred in 24 patients (8.2%), including 15 (5.1%) that led to vedolizumab discontinuation (1 case of pulmonary tuberculosis and 1 rectal adenocarcinoma).

Conclusions: In a cohort of patients with CD or UC who failed previous anti-tumor necrosis factor therapy, approximately one third of patients achieved steroid-free clinical remission after 14 weeks of induction therapy with vedolizumab. This agent had an acceptable safety profile in these patients.

Keywords: Cell Adhesion; Drug; IBD; Inhibitor.

PubMed Disclaimer

Publication types

MeSH terms